140 related articles for article (PubMed ID: 7915989)
1. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses.
La Mantia L; Eoli M; Milanese C; Salmaggi A; Dufour A; Torri V
Eur Neurol; 1994; 34(4):199-203. PubMed ID: 7915989
[TBL] [Abstract][Full Text] [Related]
2. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results.
Milanese C; La Mantia L; Salmaggi A; Campi A; Eoli M; Scaioli V; Nespolo A; Corridori F
Eur Neurol; 1989; 29(1):10-4. PubMed ID: 2540005
[TBL] [Abstract][Full Text] [Related]
3. High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients.
Dufour A; Salmaggi A; La Mantia L; Eoli M; Nespolo A; Milanese C
Int J Neurosci; 1994 Mar; 75(1-2):119-28. PubMed ID: 7914185
[TBL] [Abstract][Full Text] [Related]
4. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.
Frequin ST; Barkhof F; Lamers KJ; Hommes OR; Borm GF
Acta Neurol Scand; 1992 Sep; 86(3):291-7. PubMed ID: 1384263
[TBL] [Abstract][Full Text] [Related]
5. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.
Compston DA; Milligan NM; Hughes PJ; Gibbs J; McBroom V; Morgan BP; Campbell AK
J Neurol Neurosurg Psychiatry; 1987 May; 50(5):517-22. PubMed ID: 2953865
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.
Durelli L; Cocito D; Riccio A; Barile C; Bergamasco B; Baggio GF; Perla F; Delsedime M; Gusmaroli G; Bergamini L
Neurology; 1986 Feb; 36(2):238-43. PubMed ID: 3511404
[TBL] [Abstract][Full Text] [Related]
7. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis.
Sellebjerg F; Christiansen M; Jensen J; Frederiksen JL
Eur J Neurol; 2000 May; 7(3):281-9. PubMed ID: 10886311
[TBL] [Abstract][Full Text] [Related]
8. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.
Trotter JL; Garvey WF
Neurology; 1980 Jul; 30(7 Pt 1):702-8. PubMed ID: 6967197
[TBL] [Abstract][Full Text] [Related]
9. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR
Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063
[TBL] [Abstract][Full Text] [Related]
10. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis.
Wang HY; Matsui M; Araya S; Onai N; Matsushima K; Saida T
J Neurol Sci; 2003 Dec; 216(1):61-6. PubMed ID: 14607304
[TBL] [Abstract][Full Text] [Related]
11. Early immunosuppressive effect of parenteral methylprednisolone in the treatment of multiple sclerosis.
Durelli L; Baggio GF; Bergamasco B; Barile C; Cocito D; Delsedime M; Perla F; Riccio A; Bergamini L
Acta Neurol (Napoli); 1985; 7(3-4):338-44. PubMed ID: 3904340
[No Abstract] [Full Text] [Related]
12. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis.
Zorzon M; Zivadinov R; Locatelli L; Giuntini D; Toncic M; Bosco A; Nasuelli D; Bratina A; Tommasi MA; Rudick RA; Cazzato G
Eur J Neurol; 2005 Jul; 12(7):550-6. PubMed ID: 15958096
[TBL] [Abstract][Full Text] [Related]
13. Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters.
Anderson TJ; Donaldson IM; Sheat JM; George PM
Aust N Z J Med; 1990 Dec; 20(6):794-7. PubMed ID: 2291728
[TBL] [Abstract][Full Text] [Related]
14. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[TBL] [Abstract][Full Text] [Related]
15. Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.
Milanese C; Salmaggi A; La Mantia L; Campi A; Eoli M; Savoiardo M; Bianchi G; Nespolo A
J Neurol Neurosurg Psychiatry; 1990 Jul; 53(7):554-7. PubMed ID: 1697334
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
17. The effect of methylprednisolone on lymphocyte phenotype and function in patients with multiple sclerosis.
Kirk P; Compston A
J Neuroimmunol; 1990 Jan; 26(1):1-8. PubMed ID: 1967180
[TBL] [Abstract][Full Text] [Related]
18. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.
Martínez-Cáceres EM; Barrau MA; Brieva L; Espejo C; Barberà N; Montalban X
Clin Exp Immunol; 2002 Jan; 127(1):165-71. PubMed ID: 11882048
[TBL] [Abstract][Full Text] [Related]
19. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
Grau-López L; Teniente-Serra A; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Martínez-Cáceres EM; Ramo-Tello C
Mult Scler; 2015 Apr; 21(5):646-50. PubMed ID: 25145693
[TBL] [Abstract][Full Text] [Related]
20. Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future.
Hommes OR; Barkhof F; Jongen PJ; Frequin ST
Mult Scler; 1996 Jul; 1(6):327-8. PubMed ID: 9345410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
